Abstracts tagged "Patient reported outcomes"

Abstract Number: 1403 • ACR Convergence 2025
Treatment of sleep apnoea syndrome in patients with primary Sjögren’s disease improves symptoms and activity of disease
Anna Kuhn¹, Magdalena Seng², Björn Christian Frye³, Sebastian Fähndrich³, Lydia Vollmer³, Jacques-eric GOTTENBERG⁴, Florian Kollert⁵, Reinhard Voll⁶ and Stephanie Finzel⁷, ¹¹University Medical Center, Department of Rheumatology and Clinical Immunology, Freiburg, Germany, Freiburg, Germany, ²¹University Medical Center, Department of Rheumatology and Clinical Immunology, Freiburg, Germany; ²University Medical Center, Department of Radiology and Nuclear medicine, Basel, Switzerland, Freiburg, Germany, ³³University Medical Center, Department of Pulmonology, Freiburg, Germany, Freiburg, Germany, ⁴Hautepierre Hospital, STRASBOURG, Alsace, France, ⁵¹University Medical Center, Department of Rheumatology and Clinical Immunology, Freiburg, Germany; Department of Rheumatology and Immunology, Inselspital, Bern University Hospital, University of Bern, Bern; Switzerland Department of Rheumatology, University Hospital Basel, Basel, Switzerland, Basel, Switzerland, ⁶University Medical Center Freiburg, Freiburg, Germany, ⁷Department of Rheumatology and Clinical Immunology, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany
Background/Purpose: About 70% of patients with primary Sjögren's disease (pSjD) suffer from fatigue. Fatigue is associated with functional deficits(1), leading to anxiety, depression and reduced…
Abstract Number: 1103 • ACR Convergence 2025
Validation of the Health Assessment Questionnaire Disability Index in Immune Checkpoint Inhibitor-Induced Inflammatory Arthritis
Kayla Chubbs¹, Carrie Ye², Shahin Jamal³, Marie Hudson⁴, Janet Pope⁵, Tom Appleton⁶, Sabrina Hoa⁷, Alexandra Saltman⁸, Megan Himmel⁸, Nancy Maltez⁹, Faiza Khokhar¹⁰, Alexandra Ladouceur¹¹, Ines Colmegna¹², May Choi¹³, Manar Elsayed² and Janet Roberts¹, ¹Dalhousie University, Halifax, NS, Canada, ²University of Alberta, Edmonton, AB, Canada, ³University of British Columbia, Vancouver, BC, Canada, ⁴McGill University, Montréal, QC, Canada, ⁵University of Western Ontario, London, ON, Canada, ⁶Western University, London, ON, Canada, ⁷University of Montreal, Brossard, QC, Canada, ⁸University of Toronto, Toronto, ON, Canada, ⁹Department of Medicine, Division of Rheumatology, The Ottawa Hospital, University of Ottawa, Ottawa, Canada., Ottawa, ON, Canada, ¹⁰Hamilton Ontario, Hamilton, ON, Canada, ¹¹University of Montreal, Montreal, QC, Canada, ¹²The Research Institute of the McGill University Health Centre, Montréal, QC, Canada, ¹³University of Calgary, Calgary, AB, Canada
Background/Purpose: The use of immune checkpoint inhibitors (ICI) continues to increase with an expanding number of indications across varying cancer types and stages. ICIs can…
Abstract Number: 0499 • ACR Convergence 2025
Olokizumab Improves Patient-Reported Outcomes in Rheumatoid Arthritis MTX-IR and TNF-IR Patients up to 106 Weeks (Results from Clinical Phase III Program)
Roy Fleischmann¹, Eugen feist² and Josef Smolen³, ¹Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX, ²Helios Department of Rheumatology, Vogelsang-Gommern, Germany, ³Division of Rheumatology, Department of Medicine ³, Medical University of Vienna, Vienna, Austria, Vienna, Austria
Background/Purpose: Olokizumab (OKZ), an interleukin-6 inhibitor approved in several countries for managing rheumatoid arthritis (RA), was evaluated in previous phase III RCTs, demonstrating changes in…
Abstract Number: 0367 • ACR Convergence 2025
Differences in Self-Reported Medication Nonadherence and its Drivers in Young Adults versus Older Adults with Systemic Lupus Erythematosus
Hannah Concannon¹, Kai Sun², Jennifer Rogers³, Megan Clowse⁴, Rachel Randell², Mithu Maheswaranathan⁵, Lisa Criscione-Schreiber⁵, Nathaniel Harris⁶, Amanda Eudy⁷ and Rebecca Sadun², ¹Duke University School of Medicine, Chapel Hill, NC, ²Duke University, Durham, NC, ³Duke, Durham, NC, ⁴Duke University, Chapel Hill, NC, ⁵Duke University School of Medicine, Durham, NC, ⁶Duke University Medical Center, Durham, NC, ⁷Duke University, Raleigh, NC
Background/Purpose: Medication adherence poses a challenge for patients with SLE, especially younger patients, who often experience both more active disease and more intensive treatments than…
Abstract Number: 2426 • ACR Convergence 2025
Physical Activity Patterns and Health-Related Quality of Life in Middle-Aged and Older Adults with Systemic Lupus Erythematosus
Sarah Lieber¹, Neha Nagpal¹, Julia Nguyen², Ashley Chung², Dongmei Sun¹, Iris Navarro-Millan³, M. Carrington Reid⁴ and Lisa Mandl¹, ¹Hospital for Special Surgery, New York, NY, ²Hospital for Special Surgery, New York, ³Weill Cornell Medicine, Hospital for Special Surgery, Poughkeepsie, NY, ⁴Weill Cornell Medicine, New York, NY
Background/Purpose: The benefits of physical activity are well established in older adults in the general population. Among older adults with rheumatic and musculoskeletal diseases, including…
Abstract Number: 1733 • ACR Convergence 2025
Risk factors for the development of immune checkpoint inhibitor-related adverse events, including rheumatology-related presentations
Adela Francis-Malave¹, Terri Laufer², Joshua Baker³, Kyra Sacksith⁴, Melissa Batson⁴ and Sokratis Apostolidis³, ¹University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, ²University of Pennsylvania, Bala Cynwyd, PA, ³University of Pennsylvania, Philadelphia, PA, ⁴University of Pennsylvania, Philadelphia
Background/Purpose: While immune-related adverse events (irAEs) are a commonly reported complication of immune checkpoint inhibitor (ICI) therapy, factors associated with their development remain poorly defined.…
Abstract Number: 1402 • ACR Convergence 2025
Understanding Fatigue Through Patients’ Eyes: Development of a Novel Questionnaire Capturing the Complexity of Real-Life Fatigue in Sjögren’s Disease
Saviana Gandolfo¹, Flavia Riccio², Mariachiara Visconti³, Corrado Parlati³, Nicola Della Rossa⁴, Enrico Tirri⁵ and Francesco Ciccia³, ¹Rheumatology Unit, Ospedale del mare, Naples, Naples, Naples, Italy, ²Rheumatology Section, University of Campania L. Vanvitelli, Naples, Italy, Napoli, Italy, ³Rheumatology Section, University of Campania L. Vanvitelli, Naples, Italy, Naples, Italy, ⁴Rheumatology Section, University of Campania L. Vanvitelli, Naples, Italy, Naples, ⁵Rheumatology Unit, Ospedale del mare, Naples, Italy, Naples, Italy
Background/Purpose: Fatigue is one of the most frequent, debilitating and impactful symptoms for patients with Sjögren's Disease (SjD), and one of the most challenging to…
Abstract Number: 1085 • ACR Convergence 2025
Bridging the Gap: The Use of Patient Joint Self-Assessment in RA Treatment Response Evaluation
Sri Lakshmi Sathiyaseelan¹, Sandeep Kansurkar², Kavita Krishna³ and Varsha Bhatt⁴, ¹Bharati Vidyapeeth medical college and hospital, chennai, Tamil Nadu, India, ²Bharti vidyapeeth (DTU) Medical College, Pune, Pune, Maharashtra, India, ³Bharati Vidyapeeth University Medical College and Hospital, Pune, Maharashtra, India, ⁴Department of Clinical Immunology and Rheumatology, Bharati Vidyapeeth (Deemed To Be) University Medical College,Pune, Pune, Maharashtra, India
Background/Purpose: Rheumatoid arthritis presents with multiple joint pains and it is traditionally, examined by the clinicians. The utility of patient self‐joint counts has become an…
Abstract Number: 0488 • ACR Convergence 2025
Early and Sustained Improvements in Disease Activity and Patient-Reported Outcomes in Patients Treated with Filgotinib for Rheumatoid Arthritis: Up to 2-Year Interim Real-World Data From FILOSOPHY and PARROTFISH
Jérôme Avouac¹, Neil Betteridge², Karen Bevers³, Gerd Burmester⁴, Roberto Caporali⁵, Ouafia Bouzid⁶, Thomas Debray⁶, Carole Van der Donckt⁶, James Galloway⁷, Susana Romero-Yuste⁸ and Patrick Verschueren⁹, ¹Hôpital Cochin, AP-HP Centre - Université Paris Cité, Paris, France, ²Neil Betteridge Associates, London, United Kingdom, ³Sint Maartenskliniek, Nijmegen, Netherlands, ⁴Department of Rheumatology and Clinical Immunology, Charité – Universitätsmedizin Berlin, Berlin, Germany, ⁵University of Milan and ASST Gaetano Pini-CTO, Milano, Italy, ⁶Alfasigma S.p.A., Bologna, Italy, ⁷King's College London, London, United Kingdom, ⁸University Hospital Complex of Pontevedra, Pontevedra, Spain, ⁹Rheumatology, University Hospital Leuven and Skeletal Biology and Engineering Research Centre, KU Leuven, Leuven, Belgium
Background/Purpose: FILOSOPHY (NCT04871919) and PARROTFISH (NCT05323591) are ongoing, prospective, observational Phase 4 studies of filgotinib in patients (pts) with rheumatoid arthritis (RA) in Europe. In…
Abstract Number: 0366 • ACR Convergence 2025
Dental Findings in Patients With Rheumatic Diseases and Its Association With Self-Perceived Oral Health
Fernanda M. Garcia-Garcia¹, Margarita Isabel Alarcon-Jarquin², Vanessa L. Lopez-Flores², Gabriel P. Castro-Cruz³, Carlos I. Estrada-Anguiano³, Jennifer Garcia-Bravo³, Aleydis Gonzalez-Melendez³, Gabriel Figueroa-Parra³, Dionicio A. Galarza-Delgado¹ and Janett C. Riega-Torres⁴, ¹Rheumatology Service, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Monterrey, Mexico, ²Rheumatology Service, University Hospital “Dr. José Eleuterio González”, Universidad Autónoma de Nuevo León, Monterrey, Nuevo Leon, Mexico, ³Rheumatology Service, Hospital Universitario “Dr. Jose Eleuterio Gonzalez”, Universidad Autonoma de Nuevo Leon, Monterrey, Mexico, ⁴Rheumatology Service, Hospital Universitario “Dr. Jose Eleuterio Gonzalez”, Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo Leon, Mexico
Background/Purpose: Oral health conditions are frequent in patients with rheumatic diseases and can impact daily function and quality of life. Factors such as chronic inflammation…
Abstract Number: 2379 • ACR Convergence 2025
Predicting Type 1 and Type 2 SLE Activity Using the LupusPRO
Amanda Eudy¹, Megan Clowse², Meenakshi Jolly³, Dana Burshell⁴, David Pisetsky⁵, Connor Drake⁴, Tamara Somers⁶, Ralph Snyderman⁷, Kai Sun⁸, Rebecca Sadun⁸, Lisa Criscione-Schreiber⁴, Mithu Maheswaranathan⁴, Nathaniel Harris⁵, Jayanth Doss⁹ and Jennifer Rogers⁴, ¹Duke University, Raleigh, NC, ²Duke University, Chapel Hill, NC, ³Rush University, Chicago, ⁴Duke University School of Medicine, Durham, ⁵Duke University Medical Center, Durham, NC, ⁶Duke University School of Medicine, Durham, NC, ⁷Duke Center for Personalized Health Care, Durham, NC, ⁸Duke University, Durham, NC, ⁹Division of Rheumatology and Immunology, Duke University Department of Medicine, Durham, NC
Background/Purpose: The Type 1 & 2 SLE Model separates lupus disease activity into two groups: Type 1 (e.g. arthritis, rash, nephritis) and Type 2 SLE…
Abstract Number: 1689 • ACR Convergence 2025
Addressing Perceived Discrimination in Lupus Care: Enhancing Patient Empowerment and Health Equity Through Education and Support
Kimberly Cabrera¹, Priscilla Calvache², Lillian Mendez³, Giselle Morales⁴ and Jillian Rose-Smith², ¹Hospital for Special Surgery, New York, ²Hospital for Special Surgery, New York, NY, ³Patient Advocate, Carteret, NJ, ⁴Hospital for Special Surgery, Glendale, NY
Background/Purpose: SLE is a life-threatening autoimmune disease that disproportionately affects African American (AA), Hispanic/Latino, & Asian populations. These communities experience serious health disparities, including more…
Abstract Number: 1396 • ACR Convergence 2025
Influence of Age on Daily Impairment, Patient Empowerment, Activation and Engagement in Patients with Sjögren’s Disease
Esra Sevimli¹, Berceste Polat², Busra Sari³, Can Akmansoy², Burcu Aksoy⁴, Omur Mumcu⁵, Hatice Kalender³, Aysegul Avcu⁶, Mustafa Erdogan⁷, Nur Sisman⁸, Farida Fortune⁹, Gonca Mumcu¹⁰ and Nevsun Inanc⁷, ¹¹Institute of Health Sciences, Marmara University, Department of Health Management, Istanbul, Turkey, ²Marmara University, Faculty of Dentistry, Istanbul, Turkey, ³Institute of Health Sciences, Marmara University, Department of Health Management, Istanbul, Turkey, ⁴Istanbul University-Cerrahpasa, Institute of Postgraduate Education, Department of Health Management, Istanbul, Turkey, ⁵Yeditepe University, Faculty of Dentistry, Istanbul, Turkey, ⁶Marmara University, Istanbul, Turkey, ⁷Marmara University, School of Medicine, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, ⁸Marmara University, Faculty of Health Sciences, Istanbul, Turkey, ⁹Barts and The London School of Medicine and Dentistry, Centre Immunobiology and Regenerative Medicine, Queen Mary University of London, London, United Kingdom, ¹⁰Faculty of Dentistry, Istanbul Okan University, Istanbul, Turkey
Background/Purpose: Patient-centred care and improvement of daily life are the main components in chronic disease management. The aim of the study was to determine associations…
Abstract Number: 1055 • ACR Convergence 2025
The Price of Relief: Examining the Role of Insurance in High-Cost Medication Use
Antara Dattagupta¹, Colin Diffie² and Sana Cheema², ¹Washington University in St. Louis, St. Louis, MO, ²Washington University in St. Louis, St. Louis
Background/Purpose: High-cost biologic therapies are integral to the management of rheumatoid arthritis (RA), yet access to these agents may be influenced by insurance type, particularly…
Abstract Number: 0470 • ACR Convergence 2025
Characterization of Patients With Rheumatoid Arthritis Based on Distinct Patterns of Pain Improvement Following Treatment With Filgotinib: A Post Hoc Analysis of FINCH 1
Peter Taylor¹, Yoshiya Tanaka², Louis Dron³, Katrien Van Beneden⁴, Gerd Burmester⁵ and Bruno Fautrel⁶, ¹University of Oxford, Oxford, United Kingdom, ²University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ³Cytel, Toronto, Canada, ⁴Alfasigma S.p.A., Bologna, Italy, ⁵Department of Rheumatology and Clinical Immunology, Charité – Universitätsmedizin Berlin, Berlin, Germany, ⁶Sorbonne Université - APHP, Department of Rheumatology, Hôpital Pitié-Salpêtrière, Inserm UMRS ¹¹³⁶-⁵, PARIS, France, Paris, France
Background/Purpose: Janus kinase inhibitors have been shown to ameliorate pain as well as inflammation in patients with rheumatoid arthritis (RA). Pain response trajectories were modeled…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].